Advertisement

Disease & Tumor Database

Navigating Chronic Lymphocytic Leukemia: The Critical Importance of the First 90 Days
Navigation Tools published on April 20, 2023 in Patient Advocacy/Empowerment , Chronic Lymphocytic Leukemia
Patients with chronic lymphocytic leukemia (CLL) cannot expect to follow a textbook example of “how CLL is treated,” as each case is different based on patient age, comorbidities, and specifics related to mutations/severity. Veteran navigators offer expert commentary on CLL disease state, treatment considerations, psychosocial impact, and more.
Learn More
CAR T-Cell Therapy: Implications for Navigation Practice
Navigation Tools published on April 20, 2023 in Multiple Myeloma
This 16-page resource is designed for oncology nurse and patient navigators who are caring for patients with multiple myeloma undergoing chimeric antigen receptor (CAR) T-cell therapy.
Learn More
Navigating Multiple Myeloma: The Critical Importance of the First 90 Days
Navigation Tools published on April 19, 2023 in Multiple Myeloma
A comprehensive update on multiple myeloma to include diagnostic tests, treatments, and related navigation strategies. Supported by Janssen Pharmaceuticals/Legend Biotech.
Learn More
Navigating Oral Therapy in Breast Cancer: Practice Strategies to Promote Medication Adherence
Video Library published on November 9, 2022 in Breast Cancer
The Academy of Oncology Nurse & Patient Navigators (AONN+) and Eli Lilly and Company Medical Affairs are pleased to present a live webinar designed to facilitate conversations with patients regarding adherence to breast cancer treatments. Attendees will have an opportunity to participate in a live Q&A following the presentation.
Learn More
Optimizing Bispecific Antibody Therapy in Multiple Myeloma: A Resource Guide for Nurse and Patient Navigators
Navigation Tools published on October 13, 2022 in Multiple Myeloma

The therapeutic landscape of multiple myeloma (MM) has undergone a remarkable evolution over the past 2 decades. The development and application of novel agents and new generations of drugs, such as proteasome inhibitors, immunomodulatory drugs, and monoclonal antibody–based therapies, have resulted in improved prognosis and extended survival of patients with MM. Although these therapeutic advances are opportune and transformative, they add complexity to the MM clinical algorithms.

This resource guide is a review of bispecific antibodies, one of the new therapies currently being studied in clinical trials for patients with relapsed/refractory MM (RRMM), and best practices for oncology nurses and nurse and patient navigators, social workers, care coordinators, and advanced practice providers in supporting patients with RRMM who may be eligible for bispecific antibody–based treatment.

Learn More
Breast Cancer Patients’ Perception of Their Body Image
Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG
AONN+ Blog published on June 27, 2022 in Breast Cancer
For patients with breast cancer who need surgery, we should encourage them to think this way—“when you look down, don’t see that your breast is gone; see instead that the cancer is gone.”
Learn More
Social Determinants of Breast Cancer for Young Survivors
Mu Lin
AONN+ Blog published on May 9, 2022 in Adolescents and Young Adults, Breast Cancer
Adolescent and young adult survivors of breast cancer may face many of the same challenges as other cancer survivors, but some concerns, such as childcare and infertility, are especially salient for them.
Learn More
Lung Cancer Screening Benefits and Guidelines
Mu Lin
AONN+ Blog published on March 18, 2022 in Lung Cancer
Lung cancer screening can help detect the cancer early and facilitate treatment that is likely to be curative. Guidelines have been developed for clinicians to interpret screening results and recommend management.
Learn More
Cerianna PET-CT: Identifying Patients Who May Benefit
Gary Ulaner, MD, PhD, FACNM
Video Library published on February 3, 2022 in Molecular PET Imaging, Estrogen Receptor, Breast Cancer
A recent AONN+ annual conference session discussed an FDA-approved PET imaging agent, which is used as an adjunct to biopsy for the detection of estrogen receptor (ER)-positive lesions to help inform treatment selection for patients with recurrent or metastatic breast cancer.
Learn More
Breast Cancer Risks for Those Taking Female Hormones
Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG
AONN+ Blog published on October 22, 2021 in Breast Cancer
Female hormones serve as fuel for more than 70% of breast cancers. This is important to consider when meeting patients who may be taking female hormones.
Learn More
Page 1 of 4
Results 1 - 10 of 37
 

ASSOCIATION

 

MEMBERSHIP

 
Visit the Website
Visit the Website

Privacy Policy   |   Terms of Use
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators®   |   PO Box 563, Cranbury, NJ 08512   |    This email address is being protected from spambots. You need JavaScript enabled to view it.   |    732-992-1532
AONN+ DBA AONN+ is a 501(c)(6) organization under federal tax guidelines. AONN+ Foundation for Learning, Inc. a 501(c)(3) organization under federal tax guidelines.
AONN+ Advantage, LLC, a wholly owned subsidiary of AONN+.